[
  {
    "ts": "2026-01-31T07:05:31+00:00",
    "headline": "How Investors May Respond To Cencora (COR) Deepening Its Rare Disease Services Through Curant Collaboration",
    "summary": "On January 22, 2026, Curant Health’s Curant Rare announced a collaboration with Cencora that combines Cencora’s commercialization and logistics capabilities with Curant Rare’s specialty pharmacy and patient-engagement services to support rare disease therapies. This partnership is designed to give rare disease drug developers integrated access to real-world evidence, patient-reported outcomes and market access support, aiming to smooth complex regulatory and access hurdles. With growing...",
    "url": "https://finance.yahoo.com/news/investors-may-respond-cencora-cor-070531502.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "141ebf7d-5598-3d37-8a60-de76018c467f",
      "content": {
        "id": "141ebf7d-5598-3d37-8a60-de76018c467f",
        "contentType": "STORY",
        "title": "How Investors May Respond To Cencora (COR) Deepening Its Rare Disease Services Through Curant Collaboration",
        "description": "",
        "summary": "On January 22, 2026, Curant Health’s Curant Rare announced a collaboration with Cencora that combines Cencora’s commercialization and logistics capabilities with Curant Rare’s specialty pharmacy and patient-engagement services to support rare disease therapies. This partnership is designed to give rare disease drug developers integrated access to real-world evidence, patient-reported outcomes and market access support, aiming to smooth complex regulatory and access hurdles. With growing...",
        "pubDate": "2026-01-31T07:05:31Z",
        "displayTime": "2026-01-31T07:05:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5bbfed68f38b88802c34438f171910fe",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yZDfW2I2yn2QrcEB5PeLig--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5bbfed68f38b88802c34438f171910fe.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wVD6QXOWcqhYFXmKp9sfWw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5bbfed68f38b88802c34438f171910fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-cencora-cor-070531502.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-cencora-cor-070531502.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "COR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-31T14:36:00+00:00",
    "headline": "Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)’s Growth Story Gains Momentum",
    "summary": "Cencora, Inc. (NYSE:COR) is one of the best healthcare stocks to buy for 2026. On January 29, Morgan Stanley upgraded Cencora Inc. (NYSE:COR) from Equalweight to Overweight and raised its price target to $400, citing the company’s strong position in specialty pharmaceuticals and its pending majority acquisition of OneOncology. The firm also highlighted Cencora’s plans […]",
    "url": "https://finance.yahoo.com/news/analysts-lift-ratings-price-targets-143600505.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "6a7be562-24e4-35d0-a86a-33377c767757",
      "content": {
        "id": "6a7be562-24e4-35d0-a86a-33377c767757",
        "contentType": "STORY",
        "title": "Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)’s Growth Story Gains Momentum",
        "description": "",
        "summary": "Cencora, Inc. (NYSE:COR) is one of the best healthcare stocks to buy for 2026. On January 29, Morgan Stanley upgraded Cencora Inc. (NYSE:COR) from Equalweight to Overweight and raised its price target to $400, citing the company’s strong position in specialty pharmaceuticals and its pending majority acquisition of OneOncology. The firm also highlighted Cencora’s plans […]",
        "pubDate": "2026-01-31T14:36:00Z",
        "displayTime": "2026-01-31T14:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/91d6221e3df11e4933938a3082c41da1",
          "originalWidth": 949,
          "originalHeight": 505,
          "caption": "Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)’s Growth Story Gains Momentum",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qbitK_60Vc8oncBc9nQEQw--~B/aD01MDU7dz05NDk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/91d6221e3df11e4933938a3082c41da1.cf.webp",
              "width": 949,
              "height": 505,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wtjhuWw_GHJ65_98O46.rg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/91d6221e3df11e4933938a3082c41da1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-lift-ratings-price-targets-143600505.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-lift-ratings-price-targets-143600505.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "COR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]